Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations

(MedPage Today) -- Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized UNICORN trial from Japan...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news